Imunon narrows focus on Phase 3 ovarian cancer study as premarket shares tick up
Imunon Inc said it is reorganizing to lower costs and concentrate resources on its Phase 3 OVATION 3 trial for IMNN-001, a DNA-mediated immunotherapy for newly diagnosed advanced ovarian cancer. The stock rose 2.9% in premarket trading following the announcement. The company will cut roles not essential to the trial, revise other job descriptions a…